Baseline characteristics used in match adjustment in epcoritamab (expansion and optimization cohorts) vs mosunetuzumab cohort
| Characteristic . | Efficacy comparison (expansion cohort) . | Safety comparison (optimization cohort) . | Mosunetuzumab cohort, % (n = 90) . | ||
|---|---|---|---|---|---|
| Unadjusted epcoritamab cohort, % (n = 81) . | Adjusted epcoritamab cohort, % (ESS = 37) . | Unadjusted epcoritamab cohort, % (n = 67) . | Adjusted epcoritamab cohort, % (ESS = 16) . | ||
| Age ≥60 years | 56.8 | 50.0 | 52.2 | 50.0 | 50.0 |
| Male | 67.9 | 61.1 | 58.2 | 61.1 | 61.1 |
| ECOG PS 0 (vs 1-2) | 65.4 | 58.9 | 64.2 | 58.9 | 58.9 |
| Disease stage III-IV | 85.2 | 76.7 | 92.5 | 76.7 | 76.7 |
| FLIPI score of ≥3 | 46.9 | 44.4 | 46.3 | 44.4 | 44.4 |
| Prior CAR T therapy | 4.9 | 3.3 | 7.5 | 3.3 | 3.3 |
| Prior ASCT | 19.8 | 31.1 | 19.4 | 31.1 | 31.1 |
| POD24 | 53.1 | 52.2 | 52.2 | 52.2 | 52.2 |
| Refractory to any prior anti-CD20 therapy | 80.2 | 78.9 | 79.1 | 78.9 | 78.9 |
| Refractory to any prior anti-CD20 and alkylator therapy | 70.4 | 53.3 | 61.2 | 53.3 | 53.3 |
| Refractory to last prior therapy | 69.1 | 68.9 | 58.2 | 68.9 | 68.9 |
| Bulky disease (>6 cm) | 25.9 | 34.4 | 17.9 | 34.4 | 34.4 |
| 2 prior LOTs | 44.4 | 37.8 | 53.7 | 37.8 | 37.8 |
| 3 prior LOTs | 32.1 | 31.1 | 28.4 | 31.1 | 31.1 |
| >3 prior LOTs (vs ≤3) | 23.5 | 31.1 | 17.9 | 31.1 | 31.1 |
| Prior R2 | 18.5 | 8.9 | 31.3 | 8.9 | 8.9 |
| Characteristic . | Efficacy comparison (expansion cohort) . | Safety comparison (optimization cohort) . | Mosunetuzumab cohort, % (n = 90) . | ||
|---|---|---|---|---|---|
| Unadjusted epcoritamab cohort, % (n = 81) . | Adjusted epcoritamab cohort, % (ESS = 37) . | Unadjusted epcoritamab cohort, % (n = 67) . | Adjusted epcoritamab cohort, % (ESS = 16) . | ||
| Age ≥60 years | 56.8 | 50.0 | 52.2 | 50.0 | 50.0 |
| Male | 67.9 | 61.1 | 58.2 | 61.1 | 61.1 |
| ECOG PS 0 (vs 1-2) | 65.4 | 58.9 | 64.2 | 58.9 | 58.9 |
| Disease stage III-IV | 85.2 | 76.7 | 92.5 | 76.7 | 76.7 |
| FLIPI score of ≥3 | 46.9 | 44.4 | 46.3 | 44.4 | 44.4 |
| Prior CAR T therapy | 4.9 | 3.3 | 7.5 | 3.3 | 3.3 |
| Prior ASCT | 19.8 | 31.1 | 19.4 | 31.1 | 31.1 |
| POD24 | 53.1 | 52.2 | 52.2 | 52.2 | 52.2 |
| Refractory to any prior anti-CD20 therapy | 80.2 | 78.9 | 79.1 | 78.9 | 78.9 |
| Refractory to any prior anti-CD20 and alkylator therapy | 70.4 | 53.3 | 61.2 | 53.3 | 53.3 |
| Refractory to last prior therapy | 69.1 | 68.9 | 58.2 | 68.9 | 68.9 |
| Bulky disease (>6 cm) | 25.9 | 34.4 | 17.9 | 34.4 | 34.4 |
| 2 prior LOTs | 44.4 | 37.8 | 53.7 | 37.8 | 37.8 |
| 3 prior LOTs | 32.1 | 31.1 | 28.4 | 31.1 | 31.1 |
| >3 prior LOTs (vs ≤3) | 23.5 | 31.1 | 17.9 | 31.1 | 31.1 |
| Prior R2 | 18.5 | 8.9 | 31.3 | 8.9 | 8.9 |